Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID06599346

Study on the Effects of Mesenchymal Stem Cell Culture Supernatant on the Prevention and Treatment of Mucosal Injury in Hematology Patients

Led by The General Hospital of Western Theater Command · Updated on 2024-09-19

120

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating the effects of mesenchymal stem cell (MSC) culture supernatant on preventing and treating mucosal injuries in patients undergoing hematopoietic stem cell transplantation (HSCT). HSCT is a treatment for blood cancers and disorders but often causes severe damage to the mouth lining, skin, and bladder due to high-dose chemotherapy and radiation. This study aims to see if MSC supernatant, which contains healing substances from stem cells, can help repair these injuries and improve recovery without risks related to live cell therapies. Participants will be randomly assigned to two groups: one receives standard care, including oral rinses and pain relief, while the other receives MSC supernatant in addition to standard care. The MSC supernatant will be used as a mouthwash for oral injuries, applied topically for skin injuries, and used for bladder irrigation in bladder injuries. The study will monitor healing progress, safety, and side effects over the course of treatment. During the study, participants will have regular weekly assessments and monthly follow-ups to monitor healing using standardized injury scales and pain scores. Laboratory tests and vital signs will be checked to ensure safety. Researchers will also track infection rates, hospital stay lengths, and quality of life. The trial lasts from October 2020 to September 2025, with 120 patients expected to participate and be followed throughout the study.

CONDITIONS

Brief Title

Effects of Mesenchymal Stem Cell Supernatant on Prevention and Treatment of Skin/Mucosal Injury in Hematology Patients

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Participants aged 18 years or older.
  • Patients who have undergone hematopoietic stem cell transplantation (HSCT).
  • Patients who have developed mucosal injuries (oral, skin, or bladder) after HSCT, chemotherapy, or radiotherapy.
  • Patients who are willing to provide informed consent and comply with the study procedures.
Not Eligible

You will not qualify if you...

  • Patients with severe organ dysfunction (e.g., heart, liver, kidney failure) that could interfere with the study.
  • Patients with uncontrolled active infections.
  • Known allergies or hypersensitivity to MSC supernatant.
  • Pregnant or breastfeeding women.
  • Patients with HIV or active hepatitis B or C infections.
  • Patients who have participated in another clinical trial within the last 4 weeks.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - Up to 8 weeks

Participants receive either standard care for mucosal injuries or MSC supernatant in addition to standard care. MSC supernatant is administered based on the type of mucosal injury: as a mouthwash for oral injuries, topically for skin injuries, or bladder irrigation for bladder injuries.

Weekly visits for up to 8 weeks

Follow-up

Duration - Up to 12 weeks

Participants are monitored for safety, infection rates, hospital stay duration, and recovery progress after treatment ends.

Monthly visits for up to 4 months

Trial Site Locations

Total: 1 location

1

Department of Hematology, The General Hospital of Western Theater Command

Chengdu, Sichuan, China, 610083

Actively Recruiting

Loading map...

Research Team

H

Hao Yao, Ph.D

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

A Phase II Study of Allogeneic Hematopoietic Stem Cell Trans...

Immunodeficiency

Actively Recruiting

1 location

A Single-Arm, Single-Center Study of Amimestrocel Injection ...

Oral Mucositis

Actively Recruiting

1 location

Cardiovascular Outcomes and Risk Evaluation Among Recipients...

Hematopoietic Stem Cell Transplantation

Actively Recruiting

16 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here